Ipsen S.A. (IPSEF)
- GlobeNewswire
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. Q1 2024 Q1 2023 % change €m €m ActualCER1Growth platforms2509.7452.012.8%16.2%New medicines345.514.3n/an/aSomatuline®257.8263.2-2.0%-1.3%Other9.512.4-23.8%-20.5%Total Sales822.4741.910.9%13.3% Highlights Total-sales growth of 13.3% at CER1, or 10.9% as reported, driven by the 16.2%1 increase in sales of the growth platforms2
- GlobeNewswire
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaborationFollowing development candidate validation, Ipsen will assume responsibility for further development and commercialization, leveraging existing neuroscience expertise in movement disordersThis promising platform technology created by Skyhawk allows for the exploration of previously undruggable RNA targets with small molecules, expanding the disease target landscape1 PARIS, FR
- GlobeNewswire
Ipsen publishes its 2023 Universal Registration Document
Ipsen publishes its 2023 Universal Registration Document PARIS, FRANCE, 17 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty biopharmaceutical group, announces that its 2023 Universal Registration Document has been filed with the French Autorité des Marchés Financiers on 17 April 2024 and registered under the number D.24-0288. The document is available on ipsen.com and amf-france.org. Copies will also be available at Ipsen’s headquarters – 65 quai Georges Gorse, 92100 Boulogne-B
